Chemistry:SRT-2104
From HandWiki
Short description: Organic compound, experimental pharmaceuticum
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H24N6O2S2 |
| Molar mass | 516.64 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SRT-2104 is an experimental drug that was studied by Sirtris Pharmaceuticals as a small-molecule activator of the sirtuin subtype SIRT1. The compound progressed to Phase II human trials for Type II diabetes before development was discontinued, however it continues to be widely used in animal research into the functions of SIRT1.[1][2][3][4][5]
See also
References
- ↑ "A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes". British Journal of Clinical Pharmacology 78 (1): 69–77. July 2014. doi:10.1111/bcp.12327. PMID 24446723.
- ↑ "+ and sirtuin-activating compounds". Nature Reviews. Molecular Cell Biology 17 (11): 679–690. November 2016. doi:10.1038/nrm.2016.93. PMID 27552971.
- ↑ "Inhibition of Knee Osteoarthritis Progression in Mice by Administering SRT2014, an Activator of Silent Information Regulator 2 Ortholog 1". Cartilage 13 (2_suppl): 1356S–1366S. January 2020. doi:10.1177/1947603519900795. PMID 31989845.
- ↑ "Therapeutic Effects of SRT2104 on Lung Injury in Rats with Emphysema via Reduction of Type II Alveolar Epithelial Cell Senescence". Copd 17 (4): 444–451. August 2020. doi:10.1080/15412555.2020.1797657. PMID 32722945.
- ↑ "SIRT1 in forebrain excitatory neurons produces sexually dimorphic effects on depression-related behaviors and modulates neuronal excitability and synaptic transmission in the medial prefrontal cortex". Molecular Psychiatry 25 (5): 1094–1111. May 2020. doi:10.1038/s41380-019-0352-1. PMID 30705425.
 |  |
